Investor Relations
You may request an investor information packet or additional information by filling out our contact form. If you need additional information or have further questions, please contact investor relations at 763.656.4300 or investorrelations@vascularsolutions.com.
SEC forms, including 10-K, 8-K, 10-Q, Form 5, Form 4 and others can be found by clicking on the "SEC Filings" link to the right.
Stock Exchange Listing
Our stock trades on the NASDAQ National Market under the symbol VASC.
Stock Transfer Agent and Registrar
Wells Fargo Bank Minnesota, N.A., acts as transfer agent and registrar for Vascular Solutions and maintains all shareholder records for the company. If you have questions regarding the Vascular Solutions stock you own, stock transfers, address or name changes, lost stock certificates or duplicate mailings, please contact Wells Fargo's Shareowner Services by writing or calling:
Wells Fargo Bank Minnesota, N.A.
Shareowner Services
161 N. Concord Exchange St.
P.O. Box 64853
St. Paul, MN 55075
Toll free: 800.468.9716
Phone: 651.450.4064
Fax: 651.450.4078
Independent Auditors
Virchow, Krause & Company, LLP
7900 Xerxes Ave. S., Suite 2400
Minneapolis, MN 55431
"Forward Looking Statements"
The information in (or directly accessible from) this website contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with our limited operating history, defense of patent infringement lawsuits, adoption of our new sealing methodology, lack of profitability, lack of experience with a direct sales force, exposure to possible product liability claims, the development of new products by others, dependence on third-party distributors in international markets, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, actions by the FDA related to our products, and the loss of key vendors.
